Literature DB >> 12401752

Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD).

Ezio Faglia1, Fabrizio Favales, Patrizia Calia, Felice Paleari, Giovanni Segalini, Pier Luigi Gamba, Alberto Rocca, Nicoletta Musacchio, Arturo Mastropasqua, Gianpaolo Testori, Pietro Rampini, Flavia Moratti, Anna Braga, Alberto Morabito.   

Abstract

OBJECTIVE: To report the cardiac events in type 2 diabetic outpatients screened for unknown asymptomatic coronary heart disease (CHD) and followed for 5 years. RESEARCH DESIGN AND METHODS: During 1993, 925 subjects aged 40-65 years underwent an exercise treadmill test (ETT). If it was abnormal, the subjects then underwent an exercise scintigraphy. Of the 925 subjects, 735 were followed for 5 years and cardiac events were recorded.
RESULTS: At the entry of the study, 638 of the 735 followed subjects had normal ETT, 45 had abnormal ETT with normal scintigraphy, and 52 had abnormal ETT and abnormal scintigraphy. The 52 subjects with abnormal scintigraphy and ETT underwent a cardiological and diabetological follow-up; the subjects with just abnormal ETT had a diabetological follow-up only. During the follow-ups, 42 cardiac events occurred: 1 fatal myocardial infarction (MI), 20 nonfatal MIs, and 10 cases of angina in the 638 subjects with normal ETT; 1 fatal MI in the 45 subjects with normal scintigraphy; and 1 fatal MI and 9 cases of angina in the 52 subjects with abnormal scintigraphy. In these 52 subjects all cardiac events were significantly more frequent (chi(2) = 21.40, P < 0.0001) but the ratio of major (cardiac death and MI) to minor (angina) cardiac events was significantly lower (P = 0.002). Scintigraphy abnormality (hazard ratio 5.47; P < 0.001; 95% CI 2.43-12.29), diabetes duration (1.06; P = 0.021; 1.008-1.106), and diabetic retinopathy (2.371; P = 0.036; 1.059-5.307) were independent predictors of cardiac events on multivariate analysis.
CONCLUSIONS: The low ratio of major to minor cardiac events in the positive scintigraphy group may suggest, although it does not prove, that the screening program followed by appropriate management was effective for the reduction of risk of major cardiac events.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401752     DOI: 10.2337/diacare.25.11.2032

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  16 in total

1.  Asymptomatic patients with diabetes mellitus should be screened for coronary artery disease.

Authors:  Frans J Th Wackers
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

Review 2.  Single-photon emission computed tomography myocardial perfusion imaging in patients with diabetes.

Authors:  Gavin L Noble; Gary V Heller
Journal:  Curr Cardiol Rep       Date:  2005-03       Impact factor: 2.931

3.  Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes.

Authors:  Carmine Gazzaruso; Adriana Coppola; Tiziana Montalcini; Cinzia Valenti; Adriana Garzaniti; Gabriele Pelissero; Fabrizio Salvucci; Pietro Gallotti; Arturo Pujia; Colomba Falcone; Sebastiano B Solerte; Andrea Giustina
Journal:  Endocrine       Date:  2011-08-23       Impact factor: 3.633

Review 4.  Screening asymptomatic patients with type 2 diabetes mellitus for coronary artery disease: does it improve patient outcome?

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

Review 5.  Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A Systematic Review and Meta-analysis.

Authors:  Jing Xie; M Kamran Ikram; Mary Frances Cotch; Barbara Klein; Rohit Varma; Jonathan E Shaw; Ronald Klein; Paul Mitchell; Ecosse L Lamoureux; Tien Yin Wong
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

6.  Prevalence and predictors of an abnormal stress myocardial perfusion study in asymptomatic patients with type 2 diabetes mellitus.

Authors:  Arthur J H A Scholte; Joanne D Schuijf; Antje V Kharagjitsingh; Petra Dibbets-Schneider; Marcel P Stokkel; Ernst E van der Wall; Jeroen J Bax
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

7.  Differential Association of Microvascular Attributions With Cardiovascular Disease in Patients With Long Duration of Type 1 Diabetes.

Authors:  Daniel Gordin; Valma Harjutsalo; Liane Tinsley; Ward Fickweiler; Jennifer K Sun; Carol Forsblom; Peter S Amenta; David Pober; Stephanie D'Eon; Maya Khatri; Isaac E Stillman; Per-Henrik Groop; Hillary A Keenan; George L King
Journal:  Diabetes Care       Date:  2018-01-31       Impact factor: 19.112

Review 8.  Exercise therapy in type 2 diabetes.

Authors:  Stephan F E Praet; Luc J C van Loon
Journal:  Acta Diabetol       Date:  2009-05-29       Impact factor: 4.280

9.  Prevalence and predictors of abnormal cardiovascular responses to exercise testing among individuals with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) study.

Authors:  Jeffrey M Curtis; Edward S Horton; Judy Bahnson; Edward W Gregg; John M Jakicic; Judith G Regensteiner; Paul M Ribisl; Judith E Soberman; Kerry J Stewart; Mark A Espeland
Journal:  Diabetes Care       Date:  2010-01-07       Impact factor: 19.112

10.  Screening asymptomatic patients with diabetes for unknown coronary artery disease: does it reduce risk? An open-label randomized trial comparing a strategy based on exercise testing aimed at revascularization with management based on pharmacological/behavioural treatment of traditional risk factors. DADDY-D Trial (Does coronary Atherosclerosis Deserve to be Diagnosed and treated early in Diabetics?).

Authors:  Fabrizio Turrini; Roberto Messora; Paolo Giovanardi; Stefano Tondi; Paolo Magnavacchi; Rita Cavani; Giandomenico Tosoni; Carlo Cappelli; Elisa Pellegrini; Stefania Romano; Augusto Baldini; Romeo Giulietto Zennaro; Marco Bondi
Journal:  Trials       Date:  2009-12-23       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.